title: Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011).
abstract: In this study, we analyzed the clinical and molecular epidemiology of invasive serotype 5 (Ser5) pneumococcal isolates in four teaching hospitals in the Barcelona, Spain, area (from 1997 to 2011). Among 5,093 invasive pneumococcal isolates collected, 134 (2.6%) Ser5 isolates were detected. Although the overall incidence of Ser5-related invasive pneumococcal disease (IPD) was low (0.25 cases/100,000 inhabitants), three incidence peaks were detected: 0.63/100,000 in 1999, 1.15/100,000 in 2005, and 0.37/100,000 in 2009. The rates of Ser5 IPD were higher among young adults (18 to 64 years old) and older adults (>64 years old) in the first two peaks, whereas they were higher among children in 2009. The majority (88.8%) of the patients presented with pneumonia. Comorbid conditions were present in young adults (47.6%) and older adults (78.7%), the most common comorbid conditions being chronic obstructive pulmonary disease (20.6% and 38.3%, respectively) and cardiovascular diseases (11.1% and 38.3%, respectively). The mortality rates were higher among older adults (8.5%). All Ser5 pneumococci tested were fully susceptible to penicillin, cefotaxime, erythromycin, and ciprofloxacin. The resistance rates were 48.5% for co-trimoxazole, 6.7% for chloramphenicol, and 6% for tetracycline. Two major related sequence types (STs), ST1223 (n = 65) and ST289 (n = 61), were detected. The Colombia(5)-ST289 clone was responsible for all the cases in the Ser5 outbreak in 1999, whereas the ST1223 clone accounted for 73.8% and 61.5% of the isolates in 2005 and 2009, respectively. Ser5 pneumococci are a frequent cause of IPD outbreaks in the community and involve children and adults with or without comorbidities. The implementation of the new pneumococcal conjugated vaccines (PCV10 and PCV13) might prevent such outbreaks.
authors: Microbiology Department.
authors: Dora
authors: D
authors: Rolo
authors: Asunción
authors: A
authors: Fenoll
authors: Dionísia
authors: D
authors: Fontanals
authors: Nieves
authors: N
authors: Larrosa
authors: Montserrat
authors: M
authors: Giménez
authors: Immaculada
authors: I
authors: Grau
authors: Román
authors: R
authors: Pallarés
authors: Josefina
authors: J
authors: Liñares
authors: Carmen
authors: C
authors: Ardanuy
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D017720:Molecular Epidemiology; D011008:Pneumococcal Infections / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology* / Q000401:mortality; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology / Q000209:etiology; D012703:Serotyping; D013030:Spain / Q000453:epidemiology; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
references: Chest. 1991 Jan;99(1):147-51
references: 1984946
references: J Infect Dis. 2006 Sep 1;194(5):682-8
references: 16897668
references: PLoS One. 2011;6(12):e28547
references: 22216100
references: PLoS One. 2012;7(8):e42595
references: 22912711
references: J Clin Microbiol. 2009 Apr;47(4):1012-20
references: 19225097
references: Clin Microbiol Infect. 2011 Jul;17(7):1094-8
references: 21463396
references: J Infect Dis. 2005 Jul 15;192(2):192-9
references: 15962213
references: Med J Aust. 1993 Mar 1;158(5):340-2
references: 8474377
references: J Clin Microbiol. 2012 Nov;50(11):3472-7
references: 22875896
references: J Clin Microbiol. 1998 Dec;36(12):3447-54
references: 9817852
references: Clin Vaccine Immunol. 2011 Jan;18(1):89-94
references: 21047996
references: J Clin Microbiol. 2011 Apr;49(4):1369-75
references: 21270219
references: J Clin Microbiol. 2005 Apr;43(4):1706-15
references: 15814989
references: Clin Infect Dis. 2008 Sep 15;47(6):768-74
references: 18690803
references: J Clin Microbiol. 2005 Apr;43(4):2004-8
references: 15815045
references: J Infect Dis. 2004 Oct 1;190(7):1203-11
references: 15346329
references: Microbiology (Reading). 1998 Nov;144 ( Pt 11):3049-3060
references: 9846740
references: J Clin Microbiol. 1999 Jul;37(7):2337-42
references: 10364609
references: Emerg Infect Dis. 2008 Sep;14(9):1390-7
references: 18760005
references: Vaccine. 2010 Aug 2;28(34):5591-6
references: 20599301
references: Clin Microbiol Infect. 2010 May;16(5):402-10
references: 20132251
references: Vaccine. 2007 Mar 22;25(13):2406-12
references: 17055620
references: Vaccine. 2011 Apr 18;29(18):3372-3
references: 21396901
references: Emerg Infect Dis. 2012 May;18(5):733-40
references: 22515944
references: N Engl J Med. 2003 Mar 20;348(12):1112-21
references: 12646668
references: J Clin Microbiol. 2001 Jul;39(7):2565-71
references: 11427569
references: Clin Infect Dis. 2000 Feb;30(2):319-21
references: 10671335
references: J Clin Microbiol. 2005 Apr;43(4):1694-8
references: 15814987
references: J Clin Microbiol. 2010 May;48(5):1926-8
references: 20164267